Penn Capital Management Co Has Cut By $6.11 Million Its Five Below (FIVE) Stake; 6 Analysts Are Bullish ImmunoGen, Inc. (IMGN) Last Week

April 19, 2018 - By Stephen Andrade

Five Below, Inc. (NASDAQ:FIVE) Logo

Penn Capital Management Co Inc decreased Five Below Inc (FIVE) stake by 43.9% reported in 2017Q4 SEC filing. Penn Capital Management Co Inc sold 92,616 shares as Five Below Inc (FIVE)’s stock rose 6.48%. The Penn Capital Management Co Inc holds 118,360 shares with $7.86M value, down from 210,976 last quarter. Five Below Inc now has $4.20B valuation. The stock decreased 0.55% or $0.4157 during the last trading session, reaching $75.6443. About 54,805 shares traded. Five Below, Inc. (NASDAQ:FIVE) has risen 63.74% since April 19, 2017 and is uptrending. It has outperformed by 52.19% the S&P500.

Among 9 analysts covering Immunogen (NASDAQ:IMGN), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Immunogen had 31 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Tuesday, August 29 with “Hold”. The rating was maintained by RBC Capital Markets on Tuesday, August 29 with “Buy”. RBC Capital Markets upgraded the stock to “Outperform” rating in Thursday, July 6 report. The rating was maintained by Jefferies on Friday, September 8 with “Buy”. The company was maintained on Tuesday, October 10 by Jefferies. The rating was maintained by Canaccord Genuity on Monday, March 26 with “Buy”. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, August 30. Cantor Fitzgerald maintained ImmunoGen, Inc. (NASDAQ:IMGN) on Tuesday, May 30 with “Hold” rating. The firm has “Market Perform” rating by Leerink Swann given on Monday, May 2. The firm has “Hold” rating given on Sunday, June 4 by Cowen & Co. See ImmunoGen, Inc. (NASDAQ:IMGN) latest ratings:

06/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $5.0000 Maintain
26/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $20.0000 Maintain
26/03/2018 Broker: Jefferies Rating: Buy New Target: $15.0000 Maintain
08/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $9.0 Initiate
01/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $15.0 Maintain
31/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18 Initiates Coverage On
03/11/2017 Broker: Jefferies Rating: Buy New Target: $11.0 Maintain
03/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $10.0 Maintain

The stock decreased 4.59% or $0.49 during the last trading session, reaching $10.19. About 3.15 million shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has risen 195.97% since April 19, 2017 and is uptrending. It has outperformed by 184.42% the S&P500.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.35 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

Investors sentiment increased to 1.38 in 2017 Q4. Its up 0.22, from 1.16 in 2017Q3. It increased, as 26 investors sold ImmunoGen, Inc. shares while 39 reduced holdings. 37 funds opened positions while 53 raised stakes. 101.53 million shares or 15.77% more from 87.70 million shares in 2017Q3 were reported. Burt Wealth has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Credit Suisse Ag holds 0% or 127,793 shares. Regions Corp holds 0% or 3,556 shares. Bnp Paribas Arbitrage Sa holds 0% in ImmunoGen, Inc. (NASDAQ:IMGN) or 20,506 shares. Parametric Ltd Liability Corp reported 49,239 shares stake. Wellington Mgmt Gru Ltd Liability Partnership reported 406,661 shares. State Bank Of America De invested in 1.02M shares or 0% of the stock. Citadel Advisors Ltd owns 162,949 shares. Point72 Asia (Hong Kong) Limited reported 565 shares. Fernwood Invest Mngmt Limited invested in 0.77% or 224,500 shares. Northeast Financial Consultants, Connecticut-based fund reported 34,315 shares. Sei Investments Company holds 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 1,341 shares. Assetmark Incorporated has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 169 shares. Engineers Gate Manager Limited Partnership reported 23,200 shares stake. 12,097 were accumulated by Hightower Advsr Lc.

Since February 13, 2018, it had 0 insider buys, and 12 sales for $3.27 million activity. On Wednesday, February 21 Berkenblit Anna sold $188,540 worth of ImmunoGen, Inc. (NASDAQ:IMGN) or 17,329 shares. Wingrove Theresa sold $123,804 worth of stock or 11,379 shares. JUNIUS DANIEL M also sold $292,000 worth of ImmunoGen, Inc. (NASDAQ:IMGN) on Tuesday, February 20. Gregory Richard J. sold 34,486 shares worth $375,208. 10,000 shares were sold by Johnston David Brannon, worth $115,300 on Thursday, March 15. 67,717 ImmunoGen, Inc. (NASDAQ:IMGN) shares with value of $736,084 were sold by Enyedy Mark J. On Wednesday, February 21 Ryll Thomas sold $129,211 worth of ImmunoGen, Inc. (NASDAQ:IMGN) or 11,876 shares.

Since December 8, 2017, it had 0 insider buys, and 2 sales for $2.35 million activity. Shares for $1.01M were sold by SPECTER ERIC M. The insider Anderson Joel D sold $1.34 million.

Penn Capital Management Co Inc increased Banc Calif Inc (NYSE:BANC) stake by 77,231 shares to 741,864 valued at $15.34M in 2017Q4. It also upped Vistra Energy Corp stake by 27,186 shares and now owns 90,339 shares. Carolina Finl Corp New (NASDAQ:CARO) was raised too.

Among 21 analysts covering Five Below (NASDAQ:FIVE), 13 have Buy rating, 0 Sell and 8 Hold. Therefore 62% are positive. Five Below had 59 analyst reports since September 3, 2015 according to SRatingsIntel. On Tuesday, September 6 the stock rating was upgraded by Goldman Sachs to “Neutral”. Buckingham Research maintained Five Below, Inc. (NASDAQ:FIVE) rating on Tuesday, March 20. Buckingham Research has “Buy” rating and $78 target. M Partners maintained the stock with “Buy” rating in Tuesday, February 20 report. The rating was initiated by Longbow with “Buy” on Wednesday, October 26. The company was maintained on Monday, February 12 by RBC Capital Markets. Deutsche Bank maintained Five Below, Inc. (NASDAQ:FIVE) on Friday, January 8 with “Hold” rating. Stifel Nicolaus maintained the shares of FIVE in report on Friday, June 3 with “Buy” rating. The firm earned “Hold” rating on Monday, November 16 by Deutsche Bank. The firm has “Buy” rating given on Thursday, September 3 by Deutsche Bank. The firm has “Buy” rating given on Wednesday, January 3 by Deutsche Bank.

Five Below, Inc. (NASDAQ:FIVE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: